SCHEMBL20022797

SCHEMBL20022797

Cn1cc(C2=CC(=O)CN(CC(=O)c3ccccc3)C2)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
CREBBP Q92793 2/20 0.36
SCD O00767 1/20 0.36
SCD5 Q86SK9 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
GRIN2B Q13224 1/20 0.36
CARM1 Q86X55 1/20 0.36
BRD4 O60885 1/20 0.36
SRC P12931 1/20 0.36
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022802 0.81 MKNK1 (0.38) ALDH1A1RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL20028553 0.77 BRD4 (0.38) ALDH1A1CREBBPSCDSCD5BRD4
SCHEMBL20022788 0.74 ALDH1A1 (0.39) ALDH1A1RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL20022798 0.74 GRIN2B (0.33) RAB9ASMN1; SMN2MKNK1MKNK2SLC6A4
SCHEMBL20022803 0.73 BRD4 (0.31) MKNK1MKNK2SLC6A4SLC6A3GRIN2B
SCHEMBL18209870 0.72 MEN1 (0.44) RAB9ASMN1; SMN2CREBBPSLC6A4KMT2A
SCHEMBL20022781 0.70 SMN1; SMN2 (0.42) ALDH1A1RAB9ASMN1; SMN2SLC6A4SLC6A3
SCHEMBL15164429 0.69 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2SLC6A4SLC6A3
SCHEMBL30546565 0.66 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2SLC6A4SLC6A3
SCHEMBL9919107 0.64 BRD4 (0.59) ALDH1A1CREBBPBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093985-A1 Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections MUTABILIS (FR) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093985-A1 Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections NQO1, PEPD, LCT ALDH1A1 830/4885RAB9A 1331/4885SMN1; SMN2 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.